Molecular properties of monoamine oxidases A and B Sau-Wah KwanJ. M. BergeronC. W. Abell Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S1 - S5
Biochemistry and pharmacology of moclobemide, a prototype RIMA W. HaefelyW. P. BurkardM. Da Prada Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S6 - S14
Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide A. M. CesuraR. KettlerM. Da Prada Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S15 - S16
Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant A. ColziF. d'AgostiniM. Da Prada Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S17 - S20
Molecular neuroanatomy of monoamine oxidases in human brainstem J. G. RichardsJ. SauraM. Da Prada Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S21 - S23
Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies R. AmreinT. W. GüntertW. Schmid-Burgk Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S24 - S31
Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine M. Da PradaG. Zürcher Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S32 - S34
Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats W. BurkardF. d'AgostiniM. Da Prada Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S35 - S36
Pharmacokinetic and metabolic aspects of the moclobemide-food interaction A. F. D. ColeJ. G. BaxterD. Lalka Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S37 - S39
Influence of moclobemide on ibuprofen-induced faecal blood loss T. W. GüntertM. SchmittJ. H. G. Jonkman Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S40 - S42
MAOIs to RIMAs in anaesthesia — a literature review S. HillK. YauJ. Whitwam Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S43 - S45
Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations J. DingemanseA. KornT. W. Güntert Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S46 - S48
Behavioural toxicity of antidepressants with particular reference to moclobemide I. HindmarchJ. Kerr Section II Psychomotor Performance And Cognitive Performance Pages: S49 - S55
Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline H. AllainA. LieuryJ. M. Gandon Section II Psychomotor Performance And Cognitive Performance Pages: S56 - S61
Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo J. G. RamaekersH. F. SwijgmanJ. F. O'Hanlon Section II Psychomotor Performance And Cognitive Performance Pages: S62 - S67
Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects J. DingemanseI. BerlinA. J. Puech Section II Psychomotor Performance And Cognitive Performance Pages: S68 - S70
Differentiation between major and minor depression M. PhilippC. D. DelmoO. Benkert Section III Current Issues In Depression Pages: S75 - S78
Depression in the community: a comparison of treated and non-treated cases in two non-referred samples W. MaierD. LichtermannM. Fickinger Section III Current Issues In Depression Pages: S79 - S81
Relationship of anxiety and depression A. FrancesD. ManningM. Kline Section III Current Issues In Depression Pages: S82 - S86
Methodology of measuring the efficacy of antidepressants F. M. Quitkin Section III Current Issues In Depression Pages: S87 - S89
Methodology of measuring the efficacy of antidepressants — European viewpoint B. Woggon Section III Current Issues In Depression Pages: S90 - S92
Active control equivalence trials: some methodological aspects U. FernerN. Neumann Section III Current Issues In Depression Pages: S93 - S95
Theoretical considerations and perspectives on the onset of action of moclobemide J. -P. GachoudH. MikkelsenR. Jouvent Section III Current Issues In Depression Pages: S96 - S97
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study D. BakishJ. BradwejnL. Bulger Section IV Clinical Efficacy Pages: S98 - S101
Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III) T. BougerolC. UchidaH. Mikkelsen Section IV Clinical Efficacy Pages: S102 - S108
Efficacy of moclobemide in different patient groups: a meta-analysis of studies J. AngstM. Stabl Section IV Clinical Efficacy Pages: S109 - S113
Moclobemide and placebo in mild major depression: a double-blind randomized trial E. OseP. Holm Section IV Clinical Efficacy Pages: S114 - S115
A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients J. P. MacherC. Mirabaud Section IV Clinical Efficacy Pages: S116 - S117
A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder P. LemoineC. Mirabaud Section IV Clinical Efficacy Pages: S118 - S119
Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III E. MollM. StablR. Amrein Section IV Clinical Efficacy Pages: S120 - S122
Patients at risk of suicide and overdose G. BeaumontW. Hetzel Section V Special Patient Groups Pages: S123 - S126
Safety of moclobemide taken in overdose for attempted suicide W. Hetzel Section V Special Patient Groups Pages: S127 - S129
Use of moclobemide in children with attention deficit hyperactivity disorder G. E. TrottH. J. FrieseG. Nissen Section V Special Patient Groups Pages: S134 - S136
Depression and senile dementia of the Alzheimer type: a role for moclobemide V. Chan-Palay Section V Special Patient Groups Pages: S137 - S139
